We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Pulmonary Hypertension in COPD Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00614900
First Posted: February 13, 2008
Last Update Posted: September 18, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Aarhus University Hospital
Information provided by (Responsible Party):
Charlotte Andersen, University of Aarhus
  Purpose
The prevalence of an increased pulmonary blood pressure amongst patients with chronic obstructive pulmonary disease (COPD)is unclear. So is the impact of abnormal pulmonary blood pressure on symptoms. The aim of this study is to determine the prevalence of an increased pulmonary blood pressure in 200 patients with COPD. Furthermore we will investigate if lung function test results and blood tests can predict an increased pulmonary blood pressure, and explore whether COPD patients with a high pulmonary blood pressure have more symptoms that their co-patients.

Condition
COPD Pulmonary Hypertension

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Prevalence and Influence of Pulmonary Hypertension in COPD Patients

Resource links provided by NLM:


Further study details as provided by Charlotte Andersen, University of Aarhus:

Biospecimen Retention:   Samples With DNA
Blood samples

Enrollment: 117
Study Start Date: March 2008
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Detailed Description:

The prevalence of pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) is unclear. The presence of an abnormally increased pulmonary blood pressure worsens the prognosis of COPD, but the patients are not currently diagnosed or treated for pulmonary hypertension. The aim of this study is to determine the prevalence of pulmonary hypertension in 200 patients with COPD and explore whether it worsens functional capacity and symptoms. Furthermore we will look into whether blood gas values, NT-proBNP, CRP and lung function test result can predict which patients are at risk of having pulmonary hypertension.

Methods: All patients will be screened by echocardiography. Those with signs of pulmonary hypertension will be admitted to right heart catheterization for direct measurements of pulmonary haemodynamics.

All patients will perform a 6 minutes walk test and spirometry. Blood levels of NT-proBNP and CRP will be measured. Life quality by the St. George Questionnaire and contacts to the health care system is also assessed. Differences in these parameters are analyzed among patients with no, moderate or severe pulmonary hypertension.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients have been admitted to hospital with an exacerbation in COPD in 2006.
Criteria

Inclusion Criteria:

  • Diagnosis of COPD
  • Prior admittance to hospital with exacerbation in COPD
  • Informed consent

Exclusion Criteria:

  • Exacerbation in COPD less than 6 weeks before examination
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00614900


Locations
Denmark
Department of pulmonary diseases, Aarhus Sygehus
Århus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Aarhus University Hospital
Investigators
Study Director: Ole Hilberg, Md, Dr.med. Aarhus Universitetshospital, Aarhus Sygehus
  More Information

Responsible Party: Charlotte Andersen, MD, University of Aarhus
ClinicalTrials.gov Identifier: NCT00614900     History of Changes
Other Study ID Numbers: PreKPH-08
jnr 2007-0206
First Submitted: January 31, 2008
First Posted: February 13, 2008
Last Update Posted: September 18, 2012
Last Verified: September 2012

Keywords provided by Charlotte Andersen, University of Aarhus:
COPD
pulmonary hypertension
NT-proBNP
6 minutes walk test

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases